Baxter Presents Phase III Clinical Study Data Assessing the Use of ARTISS for Facelift Surgery

Baxter International Inc. BAX announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients. The study compared the total drainage volume for each side of the face at 24 hours post rhytidectomy, or face lift surgery. This data was presented at the American Association of Plastic Surgeons 90th Annual Meeting on April 10 in Boca Raton, Fla. “This study suggests that ARTISS can reduce drainage volumes at 24 hours after rhytidectomy surgery,” said Steve Zvi Abrams, M.D., medical director for Baxter's BioScience business. “Within the reconstructive and cosmetic plastic surgeon community, there is considerable interest in products that may be able to aid in tissue adherence.”